Jacobs Journal of Diabetes and Endocrinology

The Influence of Hashimoto’s Thyroiditis Lymphocytic Infiltration in BRAFV600E Mutation Positive Papillary Thyroid Carcinoma

*Mi Kyung Shin
Department Of Pathology, Hallym University, South Korea, Korea, Democratic People's Republic Of

*Corresponding Author:
Mi Kyung Shin
Department Of Pathology, Hallym University, South Korea, Korea, Democratic People's Republic Of
Email:jwkim@hallym.or.kr

Published on: 2018-10-25

Abstract

Background: Papillary thyroid carcinoma (PTC) and Hashimoto’s thyroiditis (HT) are frequently present together. BRAFV600E mutation may be associated with a more advanced PTC at diagnosis. We evaluated the influence of HT in BRAFV600E mutation positive PTC with clinicopathologic features. Methods: The study was performed on 66 PTC patients after surgical management from January 2012 to December 2012. BRAFV600E mutation analysis was performed by polymerase chain reaction (PCR)- based amplification of DNA extracted from paraffin-embedded tumor specimens.

Results: 24cases (36.4%) among 66 PTC patients had concomitant HT. Statistical analysis showed no significant difference between PTC with concurrent HT (PTCHT+) and without concurrent HT (PTCHT-) in several clincopathologic features (age, sex, size, multiplicity, lymph node metastasis and extrathyroidal extension). But some correlation was noted in female gender in PTCHT+(P-value; 0.082). BRAFV600E mutation was observed in 50 (75.8%) of 66 patients with PTC. 32 cases among 42 cases of PTCHT- and 18 cases among 24 cases of PTCHT+ showed BRAFV600E mutation. There was no significant difference between PTCHT+ and PTCHT- in BRAFV600E mutation rate. But in BRAF V600E mutaton positive PTC, PTCHT+ showed significant less frequent lymph node metastasis than PTCHT- (P-value; 0.035).

Conclusion: Some correlation was noted in female gender in PTCHT+(P-value; 0.082) although statistically not significant. There was no significant difference between PTCHT+ and PTCHT- in BRAFV600E mutation rate. But in BRAF V600E positive PTC, PTCHT+ showed significant less frequent lymph node metastasis than PTCHT- (P-value; 0.035)

Keywords

Hashimoto thyroiditis; Papillary thyroid carcinoma; BRAF mutation.

Introduction

PTC is the most common thyroid cancer and has been increased in number, worldwide[1]. HT is the most frequently found autoimmune thyroid disease, and around two percent of the general population suffer from this disease[2]. Ever since Dailey and his co-workers first discovered the relationship between HT and PTC in 1955, scholars started to pay increasing attention to this topic [3]. However, the pathogenesis of PTC in HT patients still remains unclear. It is supported by a number of studies that patients with PTC have more HT prevalences than those with benign and other malignant thyroid tumors [3-4]. The frequency of the association between PTC and HT ranges from 10% to 58% [5].